ONE LEAD.
ONE ENDPOINT.

Bobkov and Epishkin reported 10% better compensatory tracking, 1.8-fold fewer pursuit-tracking errors and 2.4-fold shorter visual-detection time versus placebo during simulated spaceflight and prolonged work. These are task-specific historical results. The indexed abstract omits sample size and detailed allocation. PMID 3066983 ↗.

Makarov et al. reported improved thermal tolerance and preserved work capacity with the studied drugs during intensive exertion in protective equipment. Phenibut produced the strongest protection. A companion report included placebo and several active arms at 30 ± 1°C. The shared author group and similar setting may overlap; we do not count them as independent replications. PMIDs 9162292 ↗ / 9235216 ↗.

The original 1991 paper reports 13.7% greater static-effort endurance, 6.7% shorter simple-reaction latency and half as many complex-reaction errors in treated sailors. The overall comparison included 148 Bemitil and 150 placebo participants. Detailed testing involved 20 people whose allocation is unspecified. These reported changes are not placebo-adjusted effects. Randomization and masking are not described.

A recovered 2019 monograph describes a double-blind comparison across eight groups. One Bemitil arm retained 86.2% of baseline dynamic endurance versus 68.1% with placebo (p<0.05). The chapter omits arm-specific n and a randomization procedure. This is a book-reported historical experiment, without controlled heat exposure.

The 1988 active-comparator report describes earlier and greater improvement in asthenic symptoms with Bemitil. The indexed abstract does not establish placebo control, masking or randomization. Clinical asthenia is distinct from heat-associated exertional fatigue in healthy operators.

An oral Metaprot study in healthy volunteers reported average time to peak concentration near one hour and substantial variability. It gives an exposure starting point, not proof of performance or a modern safety package. PMID 21870773 ↗.

RU2704126C2 reports 41.66 versus 27.69 minutes in male mice. The percentage is calculated from those means. Small groups and inconsistent Bemitil n=8/n=9 reporting require independent replication. This is a patent example, not an independently validated clinical result.

Measure time to a prespecified work-limit criterion at a fixed workload under controlled heat, with blinded assessment and exposure measurements. Record temperature strain and functional impairment alongside performance. Scientific leadership locks sample size, effect-size threshold and statistical analysis before testing.

By month nine, stop advancement if independent blinded replication does not reproduce a meaningful improvement at tolerated exposure, if heat strain or impairment worsens, or if the exposure/safety margin is unacceptable. Protocol thresholds are set before data are unblinded.

Bemitil matches the heat-exertion endpoint and has a relevant human research lineage. Dalargin has a stronger-looking hospital outcome signal but unresolved allocation, infusion delivery and shock-safety questions. Dalargin receives parallel scientific diligence. A stronger candidate can replace the lead after review.

The human-evidence review covers the original voyage scan, controlled-workload book reports and indexed clinical studies. It separates Bemitil-only findings from combination treatment and analytical measurements. Each entry links to its source and states what was actually reviewed.